Rosetta Aims to Use miRNAs as Biomarkers for Pharmaceutical R&D | GenomeWeb

By Doug Macron

Rosetta Genomics' top official this week provided details about a new corporate effort to leverage the company's microRNA expertise in an area outside of the diagnostics field, which had long been the company's core focus.

Speaking at the Roth OC Growth Stock conference held in Dana Point, Calif., Rosetta President and CEO Kenneth Berlin said that the company has set its sights on developing ways to use miRNAs as biomarkers to improve drug research and development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.